背景:胰腺导管腺癌(PDAC)是最致命的癌症之一,五年生存率约为5%。PDAC的发病率和死亡率都在上升,和药物治疗的结果仍然不能令人满意。一些相互矛盾的证据表明,服用阿司匹林可能会降低PDAC的风险。本研究旨在评估定期使用低剂量阿司匹林(80毫克阿司匹林片,5-7片/周)和PDAC的风险。
方法:这种前瞻性,以医院为基础,对470例PDAC患者(病例组)和526例性别和年龄匹配的对照进行了病例对照研究,在德黑兰,伊朗从2011年到2018年。对参与者进行了关于阿司匹林使用模式的访谈。数据适当时表示为平均值±SD或频率和百分比。根据列联表分析(χ2检验和Fisher精确检验)评估病例组和对照组之间的频率差异。倾向评分模型用于计算PDAC相对于阿司匹林使用的比值比(OR)和95%置信区间(95%CIs)。根据年龄调整,性别,吸烟状况,鸦片的使用,糖尿病,居住地,一级亲属的癌症家族史。
结果:本研究中,约60%的PDAC患者为男性。此外,25.2%的PDAC患者在其一级亲属中有癌症家族史,21.99%是吸烟者,13.9%是鸦片使用者,11.7%有糖尿病史。22.77%的PDAC患者和18.25%的对照组使用阿司匹林。曾经使用阿司匹林(OR:1.01,95%CI:0.89-1.14)与PDAC无关。
结论:总体而言,使用阿司匹林与PDAC风险降低无关.
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a five-year survival rate of approximately 5%. The incidence and mortality rates of PDAC are increasing, and the results of medical treatments remain unsatisfactory. Some conflicting evidence suggests that aspirin intake may reduce the risk of PDAC. This study aimed to evaluate the association between regular low-dose
aspirin use (80-mg
aspirin tablets, 5-7 tablets/week) and the risk of PDAC.
This prospective, hospital-based,
case-control study was performed on 470 PDAC patients (
case group) and 526 sex and age-matched controls, in Tehran, Iran from 2011 to 2018. The participants were interviewed regarding the patterns of
aspirin use. Data are expressed as mean±SD or frequency and percentage as appropriate. Differences in frequency between the
case and control groups were evaluated based on the analysis of the contingency table (χ2 test and Fisher\'s exact test). Propensity score models were designed to calculate odds ratios (OR) and 95% confidence intervals (95% CIs) for PDAC with respect to aspirin use, adjusted for age, sex, smoking status, opium use, diabetes mellitus, place of residence, and family history of cancer in first-degree relatives.
About 60% of PDAC patients were male in this study. Also, 25.2% of PDAC patients had a family history of cancer in one of their first-degree relatives, 21.99% were smokers, 13.9% were opium users, and 11.7% had a history of diabetes.
Aspirin was used by 22.77% of PDAC patients and 18.25% of the controls. Ever aspirin use (OR: 1.01, 95% CI: 0.89 - 1.14) was not associated with PDAC.
Overall, aspirin use was not associated with a reduced risk of PDAC.